MRIMath

Birmingham, Alabama, United States  All United States companies → — Founded 2017
Imaging AI Specialist Specialty-Focused AI
Neurosurgery Oncology Radiology
Oncology AI Radiology & Imaging AI
Early Stage / Grant-funded — $650K+
Website Claim this company

Products

i2Contour
MRIMath
Oncology AI
MRIMath i2Contour is an FDA-cleared, AI-powered web-based software for semi-automatic contouring, segmentation, and volumetric quantification of glioblastoma (GBM) from MRI images, enhancing efficiency and precision in cancer management.
Contact for pricing

See all 1 product →

About MRIMath

MRIMath LLC is an innovative medical AI company that has achieved U.S. Food & Drug Administration (FDA) 510(k) clearance for its MRIMath i2Contour cyber device and accompanying AI solution, specifically designed to enhance the efficiency and accuracy of glioblastoma (GBM) management. This advanced platform offers physicians a powerful tool to streamline complex workflows, potentially saving up to an hour per imaging study by significantly reducing the time required for tumor contouring and volumetric analysis. The technology aims to mitigate critical bottlenecks in patient care by providing precise, AI-powered and smart manual contouring tools that reduce inter-user variability and improve overall diagnostic and treatment planning precision.

The MRIMath i2Contour device integrates features such as accurate AI labeling for GBM magnetic resonance imaging (MRI) FLAIR and T1 contrast sequences, supporting robust clinical decision-making. It also facilitates secure, HIPAA-compliant cloud-based collaborative team spaces, enabling seamless workflow optimization within and across institutions, thereby enhancing access to healthcare and multidisciplinary coordination. Beyond its current FDA-cleared application for GBM, MRIMath is actively developing a comprehensive suite of AI models for broader applications within cancer and neurosciences, including AI-driven metastatic brain tumor segmentation and organs-at-risk segmentation for the brain.

What Physicians Need to Know

Specialized Focus: Glioblastoma (GBM) Management
MRIMath specializes in AI-powered solutions for the efficient and accurate management of Glioblastoma (GBM), the most common and lethal primary brain tumor in adults. Their flagship product, MRIMath i2Contour, is an FDA 510(k) cleared cyber device and AI solution designed for GBM.
AI-Powered Segmentation & Volumetric Analysis
The company provides advanced AI models for precise segmentation and volumetric analysis of GBM on MRI T1c and FLAIR sequences. These models boast high labeling accuracy (95% for T1c and 92% for FLAIR), aligning closely with radiologists' scores.
Time-Saving Efficiency
MRIMath's solutions can save physicians up to an hour per imaging study by significantly reducing the time spent on contouring and volume measurement, addressing critical bottlenecks in patient care.
Reduced Inter-User Variability
Their Smart Manual Contouring platform demonstrates remarkably low inter-user variability (under 5% for T1c and under 10% for FLAIR sequences) among radiologists, leading to more consistent and reliable results.
Secure Cloud-Based Collaboration
The platform operates in a secure, HIPAA-compliant cloud environment, enabling physicians to work from anywhere, collaborate on research projects, and consult with colleagues, optimizing workflow across institutions.
Explainable AI (XAI) & Uncertainty Quantification
Unlike 'black-box AI,' MRIMath utilizes a fully Bayesian, transparent model that provides pixel-level uncertainty maps alongside each GBM segmentation. This feature enhances trust and traceability, particularly valuable for researchers.
Expanding AI Portfolio
Beyond GBM, MRIMath is actively developing a full suite of AI models for other areas within cancer and neurosciences, including metastatic brain tumor segmentation and organs-at-risk segmentation for the brain.
Physician Tip

For physicians, MRIMath offers a significant advantage in managing glioblastoma by providing highly accurate and time-efficient AI-powered tools for MRI segmentation and volumetric analysis. This translates to faster, more precise treatment planning and longitudinal monitoring, ultimately improving patient outcomes. The secure, cloud-based platform facilitates seamless collaboration and remote access, enhancing workflow flexibility. The explainable AI with uncertainty maps builds confidence in the AI's output, allowing for better-informed clinical decisions. This technology is a game-changer for busy neuro-oncology and radiation oncology practices, streamlining complex workflows with high precision and robustness.

MRIMath's platform is designed to optimize workflow within and across institutions through collaborative team spaces and a secure cloud environment. While specific API integrations or EMR partnerships are not detailed in the provided information, the emphasis on multidisciplinary coordination and data exchange suggests a design conducive to integration within existing healthcare IT infrastructures. The platform includes a DICOM viewer, indicating compatibility with standard medical imaging formats.

Products by MRIMath

1 product in the directory

i2Contour
MRIMath
Oncology AI
MRIMath i2Contour is an FDA-cleared, AI-powered web-based software for semi-automatic contouring, segmentation, and volumetric quantification of glioblastoma (GBM) from MRI images, enhancing efficiency and precision in cancer management.
Contact for pricing

What the Web Says

MRIMath is an AI-powered medical company that has received FDA 510(k) clearance for its Cyber Device and AI Solution for Glioblastoma (GBM) management. The company's products aim to enhance the efficiency and accuracy of GBM management by providing tools for segmentation, volumetric analysis, and collaborative team spaces. Reviews from clinicians highlight the platform's user-friendliness, accuracy, and potential to significantly improve patient care and streamline workflows.

Overall: Positive

Strengths

  • User-friendly and easy to learn interface.
  • Accurate AI labeling with high precision (95% for T1c and 92% for FLAIR).
  • Reduces GBM labeling and volume measurement time by up to an hour.
  • Low inter-user variability in manual contouring (under 5% for T1c and under 10% for FLAIR).
  • Secure, HIPAA-compliant cloud environment for data storage and collaboration.
  • Streamlines complex treatment planning workflows with high precision and robustness.

Limitations

  • No specific cons were found in the provided search results for MRIMath.
  • General complaints about other 'MRI' software on Capterra and G2 include bugs, poor customer service, and lack of updates, but these do not appear to be directed at MRIMath LLC.
  • Some reviews for other 'MRI' companies on Indeed mention toxic management and limited growth opportunities.

Based on reviews from: Business Wire, MRIMath Website, FDA OKs MRIMath's Cyber Device and AI Solution for Glioblastoma - AuntMinnie.com

Last updated: 2026-07-20

Videos

News, demos, and interviews about MRIMath.

Loading videos...

Videos load interactively. If none appear, search YouTube for MRIMath →

View all on YouTube

Press & Coverage

Business Wire
MRIMath LLC, a Medical AI Company, Announces FDA 510(k) Clearance for its Cyber Device and AI Solution for Glioblastoma
MRIMath LLC, an AI company funded by the National Cancer Institute, received FDA 510(k) clearance for its MRIMath i2Contour cyber device and AI solution for glioblastoma management. This innovative tool aims to enhance the efficiency and accuracy of glioblastoma management, potentially saving physicians up to an hour per imaging study.
2024-08
Medical Device Network
US FDA clears MRIMath i2Contour and AI solution for GBM management
MRIMath, an AI-driven company supported by the National Cancer Institute, has obtained US FDA 510(k) clearance for its MRIMath i2Contour cyber device and AI solution, designed to improve the efficiency and precision of glioblastoma (GBM) management. The device uses AI-powered tools to streamline processes, minimize inter-user variability, and enhance precision, potentially improving patient outcomes and lowering healthcare costs.
2024-08
Medical Product Outsourcing
FDA OKs MRIMath's Cyber Device and AI Solution for Glioblastoma
MRIMath, an AI company funded by the National Cancer Institute, has received U.S. FDA clearance for its MRIMath i2Contour cyber device and AI to enhance glioblastoma (GBM) management. The tool can save physicians up to an hour per imaging study, reducing bottlenecks in contouring.
2024-08
Rowan University
Rowan-based startup receives FDA clearance for medical technology
MRIMath, LLC, a startup co-founded by a Rowan University professor, has received FDA clearance for its cloud-based, AI-powered medical innovation, MRIMath i2Contour, which speeds the mapping and measurement of glioblastoma brain tumors. The device is designed to improve efficiency and accuracy, potentially saving physicians hours per imaging study and reducing healthcare costs.
2024-11
PubMed (Diagnostics (Basel))
Robust AI-Driven Segmentation of Glioblastoma T1c and FLAIR MRI Series and the Low Variability of the MRIMathu00a9 Smart Manual Contouring Platform
This study evaluates MRIMath's AI models for glioblastoma (GBM) T1c and FLAIR images, comparing their contours to those of three neuro-radiologists using a smart manual contouring platform. The results highlight the low inter-user variability of the MRIMath platform and the high accuracy of its T1c and FLAIR AI models, with excellent labeling accuracy aligning with radiologists' scores.
2024-05
National Cancer Institute (NCI)
NCI Funding Helps Bring New AI-Aided Device for Glioblastoma to Market
With support from NCI's Small Business Innovation Research (SBIR) program, MRIMath, LLC developed i2Contour, a new cyber device that recently received FDA clearance for glioblastoma management. This AI-aided tool provides an interpretable, physician-in-the-loop approach for measuring and labeling GBM, aiming to assist physicians in producing accurate tumor segmentation and volumetric analysis within minutes.
2024-09
MRIMath
MRIMath Achieves ISO 13485 Certification
MRIMath announced it has achieved ISO 13485:2016 certification, an internationally recognized quality management standard for medical devices. This certification reinforces MRIMath's commitment to quality, patient safety, and continuous improvement across the full lifecycle of its medical software.
2026-03
Rowan University
Rowan Innovation Venture Fund backs tech startup, MRIMath, LLC
The Rowan Innovation Venture Fund has invested $200,000 in MRIMath, LLC, a Rowan University-affiliated startup that uses artificial intelligence to significantly improve the detection of brain tumors. MRIMath had also previously received support from the National Institutes of Health Small Business Innovation Research (SBIR) program (Phases I and II), the National Science Foundation, the New Jersey Commission on Science and Technology, and the Innovate Alabama award.
2022-10

Frequently Asked Questions

MRIMath offers AI-powered and smart manual segmentation tools, primarily for glioblastoma (GBM) and other brain tumors, including their FDA-cleared i2Contour cyber device. Their platform provides volumetric analysis, image registration, a DICOM viewer, and a collaborative TeamSpace for enhanced workflow and decision-making.
MRIMath's platform is built with government-grade cybersecurity, is HIPAA-compliant, and has achieved FDA 510(k) clearance for its i2Contour device. They employ robust security measures such as data encryption, access controls, secure authentication, and a built-in anonymization tool for DICOM files to protect patient data.
While specific pricing figures are not publicly detailed, MRIMath states its solutions are 'affordable' and 'cost-effective,' aiming to lower healthcare costs. Their pricing plan includes an online system, free apps, full access, live preview, and unlimited support.
MRIMath offers comprehensive technical support, with their pricing plan explicitly mentioning 'Support unlimited.' They also provide resources for feedback and aim to be user-friendly, facilitating seamless integration into clinical workflows.
MRIMath's platform is designed for secure, cloud-based medical imaging and features sharing and exchange tools that allow instant access and transfer of imaging studies. While direct EHR integration details aren't specified, their system is built to be compatible with clinical and research workflows and offers flexible export options like RT-DICOM and Standard DICOM.
Founded in 2017 and funded by the National Cancer Institute, MRIMath has secured FDA 510(k) clearance for its GBM solution and achieved ISO 13485 certification. The company is actively developing a full suite of AI models for cancer and neurosciences, demonstrating a commitment to long-term innovation and impact in medical AI.
MRIMath ensures patient data security and privacy through government-grade cybersecurity, HIPAA compliance, and robust measures like encryption of data in transit and at rest. They also implement access controls, secure authentication, regular security audits, and an anonymization tool to strip personal identifiers from DICOM files.
MRIMath's AI algorithms have undergone rigorous clinical validation, demonstrating high accuracy in GBM segmentation (95% for T1c and 92% for FLAIR) that aligns with radiologists' scores in FDA testing. Their smart manual contouring platform also shows low inter-user variability, further supporting its clinical efficacy.

Related Companies

QuickIntell
Chicago, IL, USA

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief
Kulpsville, PA

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed (Niedersächsisches Zentrum für KI und Kausale Methoden in der Medizin)
Hannover, Germany (Lower Saxony region)

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm
Berkeley, United States and London, United Kingdom. European office in Barcelona, Spain and Gothenburg, Sweden.

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA
London, UK

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Fraunhofer-Gesellschaft (Fraunhofer AICOS) / PALMX APPS LTD / Skin Analytics
London, United Kingdom

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
Suggest an Edit →
AI Tool Finder
AI-powered search. Results may not be comprehensive.